Loading...
Natco Pharma Stock Jumps 3% After US Launch of Multiple Myeloma Drug
LIVE TV
LOCAL
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Natco Pharma shares gain 3% on US launch of multiple myeloma drug
C
CNBC TV18
•
04-03-2026, 09:28
Natco Pharma shares gain 3% on US launch of multiple myeloma drug
•
Natco Pharma, with Breckenridge Pharmaceutical, launched Pomalidomide capsules in the US for multiple myeloma treatment.
•
The capsules are a generic version of Celgene's Pomalyst, indicated for adult patients with multiple myeloma after specific prior therapies.
•
It is also approved for AIDS-related Kaposi sarcoma and HIV-negative adult patients with Kaposi sarcoma.
•
Available in 1mg, 2mg, 3mg, and 4mg strengths, distributed via specialty pharmacies and clinics.
•
Estimated US sales of $3.2 billion by September 2025; Natco Pharma expects 180 days of shared exclusivity.
Read Full Article on Cnbc in English
✦
More like this
✦
More like this
NATCO Pharma Launches Generic Blood Cancer Drug in US Market
N
News18
Aurobindo Pharma Shares Surge on USFDA Approval for Liver Transplant Drug
C
CNBC TV18
Natco Pharma Shares Soar 2% on US Launch of Pomalidomide Capsules
M
Moneycontrol
Natco Pharma Shares Soar 11% on CDSCO Nod for Semaglutide Injection
C
CNBC TV18
Alembic Pharma gets USFDA nod for Parkinson's drug, boosts US generics presence
C
CNBC TV18
Alembic Pharma gets USFDA nod for anti-seizure drug, stock volatile
C
CNBC TV18
